Patent · US Active

Dual specificity antibodies to PD-L1 and PD-L2 and methods of use therefor

US12187799B2 · kind B2 · utility

0Cited by

1References

17Claims

0Family size

Assignee

The Board of Regents of the University of Texas System · US

Inventors

Michael A. Curran · Culver City, US
Ashvin R. JAISWAL · Houston, US
Dongxing Zha · Etna, US
Kui Shin Voo · Pearland, US
Carlo Toniatti · Houston, US
Bianka Prinz · Lebanon, US
Nga Rewa Houston · Lebanon, US
Eric Krauland · Lebanon, US

Key dates

Filing date	Mar 15, 2019
Grant date	Jan 7, 2025
Priority date	—
Expiry date	Feb 15, 2041

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2501/515
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure is directed to dual specificity antibodies which may bind to PD-L1 or PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L1 or PD-L2.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.